Skip to main content

Cancer Chemotherapy and Pharmacology

Ausgabe 6/2015

Inhalt (24 Artikel)

Review Article

Expert consensus for the management of advanced or metastatic pancreatic neuroendocrine and carcinoid tumors

Daniel Castellano, Enrique Grande, Juan Valle, Jaume Capdevila, Diane Reidy-Lagunes, Juan Manuel O’Connor, Eric Raymond

Original Article

Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patients

Toru Aoyama, Yusuke Katayama, Masaaki Murakawa, Yosuke Atsumi, Koichiro Yamaoku, Amane Kanazawa, Akio Higuchi, Manabu Shiozawa, Satoshi Kobayashi, Makoto Ueno, Manabu Morimoto, Naoto Yamamoto, Takashi Oshima, Takaki Yoshikawa, Yasushi Rino, Munetaka Masuda, Soichiro Morinaga

Original Article

DNA intercalative 4-butylaminopyrimido[4′,5′:4,5]thieno(2,3-b)quinoline induces cell cycle arrest and apoptosis in leukemia cells

Heggodu G. RohitKumar, Kittur R. Asha, Sathees C. Raghavan, Gopal M. Advi Rao

Open Access Original Article

Phase II study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced pancreatic cancer

S. Kordes, H. J. Klümpen, M. J. Weterman, J. H. M. Schellens, D. J. Richel, J. W. Wilmink

Open Access Original Article

Pharmacokinetic and pharmacodynamic profile of bendamustine and its metabolites

Mona Darwish, Mary Bond, Edward Hellriegel, Philmore Robertson Jr., James P. Chovan

Original Article

A phase I study of resminostat in Japanese patients with advanced solid tumors

Satoru Kitazono, Yutaka Fujiwara, Shinji Nakamichi, Hidenori Mizugaki, Hiroshi Nokihara, Noboru Yamamoto, Yasuhide Yamada, Eri Inukai, Osamu Nakamura, Tomohide Tamura

Original Article

A phase I/II trial of second-line chemotherapy with paclitaxel and irinotecan in fluoropyrimidine- and platinum-pretreated patients with advanced gastric cancer

Jin Won Kim, In Sil Choi, Yu Jung Kim, Kyung-Hun Lee, Keun-Wook Lee, Tae-Yong Kim, Sae-Won Han, Jee Hyun Kim, Tae-You Kim, Jong Seok Lee, Yung-Jue Bang, Seock-Ah Im, Do-Youn Oh

Original Article

Randomized study of orally administered fluorinated pyrimidines (capecitabine versus S-1) in women with metastatic or recurrent breast cancer: Japan Breast Cancer Research Network 05 Trial

D. Yamamoto, S. Iwase, Y. Tsubota, K. Ariyoshi, T. Kawaguchi, T. Miyaji, N. Sueoka, C. Yamamoto, S. Teramoto, H. Odagiri, K. Kitamura, Y. Nagumo, T. Yamaguchi

Original Article

Association of decreased mRNA expression of multidrug and toxin extrusion protein 1 in peripheral blood cells with the development of flutamide-induced liver injury

Kazuhiko Nakano, Hitoshi Ando, Shinsuke Kurokawa, Keiko Hosohata, Kentarou Ushijima, Makoto Takada, Masato Tateishi, Atsushi Yonezawa, Satohiro Masuda, Kazuo Matsubara, Ken-ichi Inui, Tatsuo Morita, Akio Fujimura

Original Article

Functional polymorphisms of ITGB1 are associated with clinical outcome of Chinese patients with resected colorectal cancer

Feng Zhou, Xiaojun Huang, Zhaohui Zhang, Yibing Chen, Xiaonan Liu, Jinliang Xing, Xianli He

Original Article

Cisplatin resistance in human cervical, ovarian and lung cancer cells

Jianli Chen, Charalambos Solomides, Hemant Parekh, Fiona Simpkins, Henry Simpkins

Original Article

A phase II trial of gefitinib monotherapy in pretreated patients with advanced non-small cell lung cancer not harboring activating EGFR mutations: implications of sensitive EGFR mutation test

Moon Ki Choi, Jung Yong Hong, Won Jin Chang, Moon Jin Kim, Sung Min Kim, Hyun Ae Jung, In-Gu Do, Yoon-la Choi, Jong-Mu Sun, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn

Original Article

Modulation of Regorafenib effects on HCC cell lines by epidermal growth factor

Rosalba D’Alessandro, Maria Grazia Refolo, Catia Lippolis, Nicola Carella, Caterina Messa, Aldo Cavallini, Brian Irving Carr

Open Access Original Article

Methylthioadenosine phosphorylase (MTAP)-deficient T-cell ALL xenografts are sensitive to pralatrexate and 6-thioguanine alone and in combination

Philip M. Tedeschi, Yamini K. Kathari, Nadine Johnson-Farley, Joseph R. Bertino

Original Article

Inhibition of SN-38 glucuronidation by gefitinib and its metabolite

Wei Li, Yafei Xing, Yong Liu

Original Article

High-dose erlotinib for refractory leptomeningeal metastases after failure of standard-dose EGFR-TKIs

Takahisa Kawamura, Akito Hata, Jumpei Takeshita, Shiro Fujita, Michio Hayashi, Keisuke Tomii, Nobuyuki Katakami

Original Article

A phase II study of pemetrexed monotherapy in chemo-naïve Eastern Cooperative Oncology Group performance status 2 patients with EGFR wild-type or unknown advanced non-squamous non-small cell lung cancer (HANSHIN Oncology Group 002)

Akito Hata, Nobuyuki Katakami, Shiro Fujita, Shigeki Nanjo, Jumpei Takeshita, Kosuke Tanaka, Toshihiko Kaneda, Akihiro Nishiyama, Takashi Nishimura, Atsushi Nakagawa, Kojiro Otsuka, Satoshi Morita, Yoshiko Urata, Shunichi Negoro

Original Article

Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines

Burcak Karaca, Mustafa Degirmenci, Ahmet Ozveren, Harika Atmaca, Emir Bozkurt, Bulent Karabulut, Ulus Ali Sanli, Ruchan Uslu

Original Article

Phase II multicenter study of adjuvant S-1 for colorectal liver metastasis: survival analysis of N-SOG 01 trial

Takehiro Kato, Keisuke Uehara, Atsuyuki Maeda, Eiji Sakamoto, Kazuhiro Hiramatsu, Eiji Takeuchi, Hidenari Goto, Yuichiro Tojima, Hiroshi Yatsuya, Masato Nagino

Original Article

PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients

Anna Koumarianou, Georgia Karayannopoulou, Georgia Gourgioti, Anna Batistatou, Mattheos Bobos, Ioannis Efstratiou, Dimosthenis Miliaras, Eleni Galani, George Pentheroudakis, Dimitrios Pectasides, Gerasimos Aravantinos, Dimitrios Bafaloukos, Pavlos Papakostas, Evangelia Razis, Haralabos P. Kalofonos, Kalliopi Petraki, Maria Sotiropoulou, Konstantine T. Kalogeras, George Fountzilas

Original Article

The newly synthesized 2-arylnaphthyridin-4-one, CSC-3436, induces apoptosis of non-small cell lung cancer cells by inhibiting tubulin dynamics and activating CDK1

Ling-Chu Chang, Yung-Luen Yu, Chin-Yu Liu, Yung-Yi Cheng, Ruey-Hwang Chou, Min-Tsang Hsieh, Hui-Yi Lin, Hsin-Yi Hung, Li-Jiau Huang, Yang-Chang Wu, Sheng-Chu Kuo

Short Communication

Targeting the EWS–FLI1 transcription factor in Ewing sarcoma

R. Tancredi, A. Zambelli, G. A. DaPrada, V. Fregoni, L. Pavesi, A. Riccardi, S. Burdach, P. J. Grohar, M. D’Incalci

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.